Argent BioPharma (ASX: RGT) narrowed its net loss to $7.7 million for FY2026, while striking a pivotal global licensing agreement for its CannEpil® epilepsy therapy that extinguishes $7.4 million in secured debt and secures ongoing royalties.
- Net loss reduced to $7.7 million from $17.8 million
- Global CannEpil® licensing deal with Splash Beverage Group extinguishes $7.4M secured debt
- Acquisition of full interest in CannPal Animal Therapeutics expands veterinary portfolio
- Administrative expenses halved following prior year one-off costs
- Secured convertible note financing facility of up to A$11 million with US-based investors
Financial Performance and Cost Control
Argent BioPharma Ltd (ASX:RGT) has reported a consolidated net loss of $7.71 million for the year ended 30 June 2026, substantially improved from a $17.84 million loss in FY2025. This narrowing of losses was driven primarily by a 43% reduction in administrative expenses, which fell from $12.1 million to $6.9 million. The company attributes the cost savings to the absence of last year’s one-off capital markets and international listing expenses, including share-based payments and elevated legal and advisory fees.
Revenue from contracts with customers remained modest at $161,187, with a gross loss of $39,618 reflecting ongoing investment in clinical programs. Cash and cash equivalents stood at $141,456 at year-end, against a net working capital deficit of $8.08 million, underscoring the company’s continued need for external funding.
CannEpil® Licensing Deal Extinguishes Secured Debt
In a transformative post-year-end development, Argent BioPharma entered into a binding global licensing agreement with Splash Beverage Group (NYSE American: SBEV) for CannEpil®, its lead neurological asset targeting drug-resistant epilepsy. The transaction, delivering US$5.5 million upfront consideration, is structured through the forgiveness of approximately US$5.5 million of outstanding secured convertible notes held by Mercer Street Global Opportunity Fund. This effectively eliminates Argent’s principal secured debt and associated security interests without issuing new shares, materially strengthening the balance sheet.
Importantly, Argent retains 100% ownership of the CannEpil® intellectual property and EU-GMP manufacturing rights, alongside a 15% royalty on net revenues from future global sales. Splash Beverage assumes responsibility for funding and executing the U.S. clinical and regulatory pathway, significantly reducing Argent’s financial and regulatory exposure while preserving substantial long-term economic participation. The licence has an initial 20-year term with automatic five-year renewals, subject to customary conditions precedent including shareholder approvals and completion of the Mercer debt exchange.
Expansion into Veterinary Therapeutics and Commercial Milestones
During FY2026, Argent completed the acquisition of AusCann Group Holdings Ltd’s 48% interest in CannPal Animal Therapeutics Pty Ltd, gaining full control of an advanced-stage veterinary cannabinoid portfolio. CannPal’s lead product, CPAT-01, demonstrated positive Phase 2C dose confirmation results in osteoarthritis pain management in dogs, meeting its primary endpoint with no serious adverse events. The company is advancing towards a Phase 3 pilot field study, pursuing partner-led funding for further development.
Argent also achieved a record commercial shipment of 1,000 CannEpil® units to Ireland, valued at approximately A$783,000 retail, reinforcing its European distribution infrastructure and reimbursed patient access. Additionally, the company filed a U.S. provisional patent for its NanoBodies platform targeting septic shock and systemic inflammatory disorders, bolstering its intellectual property portfolio.
Funding and Governance Updates
To support ongoing operations and strategic initiatives, Argent secured a convertible securities financing facility of up to A$11 million with U.S.-based institutional investors C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC. Post-year-end, the company drew down $600,000 under this facility, with further capacity available subject to investor discretion and shareholder approvals.
Board composition saw a change with the appointment of Andrew Chapman as Non-Executive Director in May 2026, bringing extensive experience in life sciences transactions and EU-GMP manufacturing assets. Chairman and Managing Director Roby Zomer continues to lead the company, holding 17 million performance rights and over 6 million shares.
Risks and Going Concern Considerations
Argent BioPharma faces ongoing funding sufficiency risks, with the Group requiring additional capital to refinance existing debt and fund corporate expenditure over the next 12 months. The company’s going concern status depends on successful completion of the CannEpil® licensing transaction, including Mercer debt extinguishment and shareholder approvals, as well as the ability to raise further debt or equity financing on acceptable terms.
Foreign exchange exposure remains significant due to USD-denominated convertible notes and cash balances, though the recent licensing deal is expected to substantially mitigate this risk. The company continues to rely on third-party distributors for product supply and has limited direct distribution capabilities.
Bottom Line?
Argent’s strategic licensing deal and funding facility mark a turning point, but execution of conditions precedent and capital raises will be critical to sustaining momentum.
Questions in the middle?
- Will shareholder approvals and Mercer debt extinguishment finalize the CannEpil® licensing deal as planned?
- How will Argent leverage its expanded veterinary portfolio to diversify revenue streams?
- What impact will foreign exchange fluctuations have on the company’s financial stability going forward?